August 18, 2017 1:58 PM ET

Pharmaceuticals

Company Overview of Shire Human Genetic Therapies, Inc.

Key Executives for Shire Human Genetic Therapies, Inc.

NameBoard RelationshipsTitleAge
Søren Tulstrup M.ScNo RelationshipsSenior Vice President and Franchise Lead of Mucopolysaccharides52
Marcio Voloch Ph.D.No RelationshipsVice President of Process Development--
Daniella M. Lutz No RelationshipsCorporate Communications Manager--

Shire Human Genetic Therapies, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Jonathan S. Leff M.B.A 169 RelationshipsDeerfield Management Company, L.P.48
Rodman W. Moorhead III 91 RelationshipsScientific Learning Corporation73
View All Board Members

Shire Human Genetic Therapies, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Nominating Committee M.B.AJonathan S. Leff169 Relationships1 Executives
Corporate Governance Committee M.B.AJonathan S. Leff169 Relationships1 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary
423.3K
Bonus
421.0K
Total Short Term Compensation
600.7K
Total Value of Options
8.1M
Compensation as of Fiscal Year
Shire Human Genetic Therapies, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

Depomed, Inc. Announces Executive Appointments
August 17, 2017 8:28 PM ET
Merz Neuroscience Appoints Kevin O'Brien as Vice President and U.S. Head of Neuroscience Business
August 17, 2017 11:45 AM ET
Acasti Pharma Announces the Election of Directors
August 17, 2017 3:52 AM ET
Bio-Path Holdings, Inc. Announces Resignation of Directors
August 16, 2017 8:06 PM ET
AIT Therapeutics, Inc. Appoints Erick J. Lucera as Director and to Serve on the Audit Committee of the Board
August 16, 2017 7:11 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Shire Human Genetic Therapies, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.